Epredia, a global leader in precision cancer diagnostics and tissue diagnostics, and Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, have announced that they have entered into a distribution agreement. This follows the announcement of a strategic investment in Lunaphore by PHC Holdings Corporation, the parent company of Epredia, which was announced on February 6, 2020.
